Barinthus Bio sets scheme exchange ratio at 0.111; merger with Clywedog to close Sept 3

Barinthus Biotherapeutics plc.

Scheme exchange ratio set at 0.111, ensuring Topco stock price meets Nasdaq minimum listing requirement.
Scheme expected effective Sept 3, 2026; BRNS ADSs to halt trading before market open that day.
Court hearing for scheme set for Sept 1, 2026 at Royal Courts of Justice, London.
After close, Topco renamed Clywedog Therapeutics Holdings, Inc., trading as CLYD on Nasdaq.
Company to delist ADSs from Nasdaq and file Form 15 to suspend reporting obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.